SENS completed a dramatic reverse stock split (reducing shares from 652M to 42M) while simultaneously taking back commercial control of their Eversense 365 CGM product from partner Ascensia and achieving breakthrough gross profit growth of nearly 3,000%.
This represents a fundamental transformation from a development-stage company dependent on partners to a commercially viable entity with direct market control. The reverse split signals management confidence in the business turnaround, while taking commercial responsibility back from Ascensia positions SENS to capture more value from their successful 365-day CGM system that recently gained both FDA and CE Mark approvals.
The financials show a company achieving commercial viability with gross profit exploding from $533K to $15.8M while maintaining disciplined cost control through reduced R&D spending (-23%) and lower interest expenses (-41%). Despite higher SG&A costs from building their own sales force (+53%) and reduced cash from operations (-46%), the company achieved positive stockholders' equity of $61M after years of deficits, supported by growing current assets (+29%) and reduced current liabilities (-37%). This financial profile suggests successful transition from R&D-focused startup to revenue-generating commercial entity.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Equity base grew 468.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
SG&A up 53.4% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Inventory surged 51.6% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Cash declined 46.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Current liabilities reduced — improved short-term financial position and working capital health.
Current assets grew 28.5% — improving short-term liquidity or inventory/receivables build.
Asset base grew 25.7% — expansion through organic growth, acquisitions, or capital deployment.
R&D spending cut 23.2% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →